局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略

国际肿瘤学杂志››2023,Vol. 50››Issue (12): 745-750.doi:10.3760/cma.j.cn371439-20230828-00140

局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略

巩合义¹, 伊艳²^,³, 张健¹, 李宝生²()

¹betway必威登陆网址附属中心医院肿瘤科，济南 250013
²山东省肿瘤防治研究院 betway必威登陆网址附属肿瘤医院放疗科山东省放射肿瘤学重点实验室，济南 250117
³天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心，天津 300060

收稿日期:2023-08-28修回日期:2023-09-19出版日期:2023-12-08发布日期:2024-01-16
通讯作者:李宝生 E-mail:baoshli1963@163.com
基金资助:
山东省自然科学基金(ZR2022ZD31)

Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy

Gong Heyi¹, Yi Yan²^,³, Zhang Jian¹, Li Baosheng²()

¹Department of Oncology， Affiliated Central Hospital of Shandong First Medical University， Jinan 250013， China
²Department of Radiation Oncology， Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University， Shandong Provincial Key Laboratory of Radiation Oncology， Jinan 250117， China
³Cancer Hospital of Tianjin Medical University， National Clinical Research Center for Cancer， Tianjin Key Laboratory of Cancer Prevention and Treatment， Tianjin Clinical Research Center for Cancer， Tianjin 300060， China

Received:2023-08-28Revised:2023-09-19Online:2023-12-08Published:2024-01-16
Contact:Li Baosheng E-mail:baoshli1963@163.com
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2022ZD31)

摘要/Abstract

摘要：

局部晚期可手术食管癌的标准治疗模式是新辅助放化疗+根治性食管切除术，但鉴于器官保留的临床需求，经新辅助放化疗达临床完全缓解后的处理策略包括等待观察（免手术）、延迟性或挽救性手术、加强系统治疗等，这些处理策略在保证患者局部控制和长期生存的基础上，可显著改善其生命质量。深入探讨这些处理策略的可行性、临床价值，期望为这部分患者提供新的治疗思路。

关键词:食管肿瘤,放化疗，辅助,等待观察,挽救性手术,系统治疗

Abstract:

The standard treatment mode for locally advanced operable esophageal carcinoma is neoadjuvant chemoradiotherapy combined with radical esophagectomy. However， considering the clinical need for organ retention， the treatment strategies for those achieving complete clinical response after neoadjuvant chemoradiotherapy include watchful waiting （omitting surgery）， delayed or salvage surgery， and strengthened systemic treatment. These treatment strategies can significantly improve the quality of patients' life while ensuring local control and long-term survival. The feasibility and clinical value of these treatment strategies are deeply explored， hoping to provide new treatment ideas for this group of patients.

Key words:Esophageal neoplasms,Chemoradiotherapy， adjuvant,Wait and see,Salvage surgery,Systemic therapy

巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.

Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.

参考文献30

[1]	Yang Y, Liu Z, Sun Y, et al. Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment in Shanghai Chest Hospital, 2016[J].J Thorac Dis,2022,14(12): 4966-4982. DOI:10.21037/jtd-22-1672. pmid:36647485
[2]	Khaitan PG, Holliday T, Carroll A, et al. Can clinical response predict pathologic response following neoadjuvant chemoradiation for esophageal cancer?[J].J Gastrointest Surg,2022,26(7): 1345-1351. DOI:10.1007/s11605-022-05315-y. pmid:35414141
[3]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J].Lancet Oncol,2018,19(7): 965-974. DOI:10.1016/S1470-2045(18)30201-8. pmid:29861116
[4]	Eyck BM, van der Wilk BJ, Noordman BJ, et al. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer[J].Trials,2021,22(1): 345. DOI:10.1186/s13063-021-05274-w. pmid:34001287
[5]	van der Wilk BJ, Noordman BJ, Neijenhuis LKA, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study[J].Ann Surg,2021,274(6): 1009-1016. DOI:10.1097/SLA.0000000000003636.
[6]	Zhang X, Eyck BM, Yang Y, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study[J].BMC Cancer,2020,20(1): 194. DOI:10.1186/s12885-020-6669-y. pmid:32143580
[7]	van der Zijden CJ, Lagarde SM, Hermus M, et al. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of surgery as needed for oesophageal cancer-2[J].BMC Cancer,2023,23(1): 327. DOI:10.1186/s12885-023-10747-z. pmid:37038138
[8]	Bedenne L, Mariette C. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (esostrate)[DB/OL]. [2019-12-20]. https://clinicaltrials.gov/ct2/show/NCT02551458.
[9]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2023[EB/OL].[2023-10-16]. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20231016021009.pdf.
[10]	Yu J, Kim JH, Kim SB, et al. Role of esophagectomy after chemoradiation therapy in patients with locally advanced squamous cell carcinoma: a comparative analysis stratified by clinical response to chemoradiation therapy[J].Cancer Res Treat,2022,54(4): 1148-1156. DOI:10.4143/crt.2021.885.
[11]	Park J, Yea JW, Oh SA, et al. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J].Radiat Oncol,2021,16(1): 219. DOI:10.1186/s13014-021-01947-7. pmid:34775988
[12]	van der Wilk BJ, Eyck BM, Hofstetter WL, et al. Chemoradiotherapy followed by active surveillance versus standard esophagectomy for esophageal cancer: a systematic review and individual patient data meta-analysis[J].Ann Surg,2022,275(3): 467-476. DOI:10.1097/SLA.0000000000004930.
[13]	Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[J].Cochrane Database Syst Rev,2017,8(8): CD010511. DOI:10.1002/14651858.CD010511.pub2.
[14]	Wang J, Qin J, Jing S, et al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: is esophagectomy always necessary? A systematic review and meta-analysis[J].Thorac Cancer,2018,9(12): 1638-1647. DOI:10.1111/1759-7714.12874. pmid:30277016
[15]	Goense L, Ruurda JP, Carter BW, et al. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using¹⁸F-FDG PET/CT[J].Eur J Nucl Med Mol Imaging,2018,45(10): 1742-1751. DOI:10.1007/s00259-018-4011-6.
[16]	Faiz Z, Kats-Ugurlu G, Mui VEM, et al. Locoregional residual esophageal cancer after neo-adjuvant chemoradiotherapy and surgery regarding anatomic site and radiation target fields: a histopathologic evaluation study[J].Ann Surg,2022,275(6): e759-e765. DOI:10.1097/SLA.0000000000004242.
[17]	Levinsky NC, Wima K, Morris MC, et al. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma[J].J Thorac Cardiovasc Surg,2020,159(6): 2555-2566. DOI:10.1016/j.jtcvs.2019.09.169. pmid:31767364
[18]	Faiz Z, Dijksterhuis WPM, Burgerhof JGM, et al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy[J].Eur J Surg Oncol,2019,45(6): 931-940. DOI:10.1016/j.ejso.2018.11.002. pmid:30447937
[19]	Park SR, Yoon DH, Kim JH, et al. A randomized phase Ⅲ trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma (ESOPRESSO)[J].Anticancer Res,2019,39(9): 5123-5133. DOI:10.21873/anticanres.13707.
[20]	Sugawara K, Yagi K, Okumura Y, et al. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T₄esophageal squamous cell carcinoma[J].Int J Clin Oncol,2020,25(4): 552-560. DOI:10.1007/s10147-019-01590-z. pmid:31828451
[21]	Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J].J Thorac Oncol,2017,12(2): 368-374. DOI:10.1016/j.jtho.2016.10.002.
[22]	郭旭峰, 孙益峰, 杨煜, 等. 食管癌根治性放化疗后挽救性手术: 单一手术组18例临床分析[J].中华胸心血管外科杂志,2018,34(2): 76-78. DOI:10.3760/cma.j.issn.1001-4497.2018.02.003.
[23]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J].J Clin Oncol,2021,39(18): 1995-2004. DOI:10.1200/JCO.20.03614.
[24]	Liu S, Wen J, Yang H, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase Ⅲ trial NEOCRTEC5010[J].Eur J Cancer,2020,138: 113-121. DOI:10.1016/j.ejca.2020.08.002.
[25]	Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery[J].J Thorac Cardiovasc Surg,2019,157(3): 1249-1259.e5. DOI:10.1016/j.jtcvs.2018.09.136. pmid:30655068
[26]	Kermani AT, Bagheri R, Taheri H, et al. Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy[J].Kardiochir Torakochirurgia Pol,2019,16(4): 186-193. DOI:10.5114/kitp.2019.91388.
[27]	Wang X, Yu N, Cheng G, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma[J].Clin Transl Med,2022,12(11): e1116. DOI:10.1002/ctm2.1116. pmid:36437506
[28]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J].N Engl J Med,2021,384(13): 1191-1203. DOI:10.1056/NEJMoa2032125.
[29]	Park S, Sun JM, Choi YL, et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase Ⅱ study[J].ESMO Open,2022,7(1): 100385. DOI:10.1016/j.esmoop.2022.100385.
[30]	Schizas D, Mylonas KS, Kapsampelis P, et al. Patients under-going surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data[J].Interact Cardiovasc Thorac Surg,2020,31(3): 299-304. DOI:10.1093/icvts/ivaa116.